Fate Uncertain As Cell Therapy Biotech Pulls Out Of J&J Deal, Restructures

 
• By Alaric DeArment
  
Generate a summary of this article
Listen to this article
Beta

The company is discontinuing its lead clinical programs and planning major layoffs as it seeks to reprioritize its pipeline and extend cash runway.

Fate Therapeutics announced the termination of its partnership with J&J and a restructuring • Source: Shutterstock

Fate Therapeutics, Inc. has initiated a major cull of its pipeline, discontinuing its lead clinical programs following the termination of its partnership with Janssen Biotech Inc.. and preparing to lay off more than 200 employees as it seeks to extend cash runway over the next three years. Instead, it will shift its focus to a small handful of much earlier allogeneic cell therapy programs.

But while it touted the next-generation programs’ potential for better cell persistence and eliminating the need for chemotherapy, analysts were...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.